US 9987253
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
granted A61KA61K31/415A61K45/06
Quick answer
US patent 9987253 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Jenrin Discovery, LLC
- Grant date
- Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/415, A61K45/06, A61P, A61P1/00